Investment analysts at Goldman Sachs (GS) initiated coverage on shares of PharMerica Corporation (PMC) in a note issued to investors on Thursday. The firm set a ‘Neutral’ rating and a $29.00 price target on the stock implying 11.71% expected return from the name’s current pps.
PharMerica Corporation shares are currently priced at 58.87x this year’s forecasted earnings compared to the industry’s -10.34x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.68 and 14.19, respectively. Price/Sales for the same period is 0.41 while EPS is 0.44. Currently there is only one analyst that rates PMC a ‘Strong Buy’, 3 rate it a ‘Buy’ and 3 rate it a ‘Hold’. No analysts rate it a ‘Sell’. PMC has a median Wall Street price target of $33.00 with a high target of $34.00.
In the past 52 weeks, shares of the Louisville, Kentucky-based institutional pharmacy services firm have traded between a low of $12.65 and a high of $30.48 and are now at $25.96. Shares are up 108.18% year-over-year and 20.74% year-to-date.
The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.